Of the wide selection of therapeutic goals, our first study of vanicoside A and B activity against melanoma focused on the V600E BRAF and MEK1 molecules taking into account the big impact of potential inhibitors of these kinase on melanoma therapy and also other cancers like colon adenocarcinoma, papillary thyroid carcinoma and others [20]. This evidence concerns the gene BRAF and melanoma.